zidovudine has been researched along with abacavir in 226 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (5.75) | 18.2507 |
| 2000's | 150 (66.37) | 29.6817 |
| 2010's | 60 (26.55) | 24.3611 |
| 2020's | 3 (1.33) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ainsworth, J; Booth, C; Bradshaw, D; Geretti, AM; Malik, S; Pattery, T; Van Houtte, M; Waters, A | 1 |
| Anderson, DJ; Gottlieb, GS; Preston, BD; Pyrak, CL; Smith, RA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barron, AC; Boojamra, CG; Chen, JM; Cihlar, T; Desai, MC; Gao, Y; Kim, CU; Laflamme, G; Lee, SK; Mackman, RL; Markevitch, DY; Parrish, JP; Petrakovsky, OV; Ray, AS; Sparacino, ML; Sperandio, D; Vela, JE | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Balzarini, J; Bourdin, C; Chamberlain, S; Derudas, M; Hamon, N; Hinsinger, K; Introini, A; Kandil, S; Kolykhalov, A; Madela, K; Margolis, L; McGuigan, C; Meneghesso, S; Pertusati, F; Serpi, M; Slusarczyk, M; Vanpouille, C; Vernachio, J | 1 |
| Arumugam, SR; Badri, KR; He, JJ; Visalli, RJ; Zhang, X; Zhao, H; Ziobrowski, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Danner, SA; de Wolf, F; Goudsmit, J; Hoetelmans, RM; Jurriaans, S; Lange, JM; Lukashov, VV; Notermans, DW; Prins, JM; Roos, M; Schuitemaker, H; Weverling, GJ | 1 |
| Saag, MS; Schooley, RT | 1 |
| Cutrell, A; Harrer, T; Harrigan, RP; Katlama, C; Lanier, RE; Massip, P; Pearce, G; Staszewski, S; Steel, H; Tortell, SM; Yeni, P | 1 |
| Gazzard, BG; Kelleher, D; LaFon, S; Lancaster, D; Romero, C; Saag, MS; Schooley, RT; Sonnerborg, A; Spreen, W; Torres, RA | 1 |
| Chittick, GE; McDowell, JA; Wang, LH | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Bendayan, R; Hong, M; Schlichter, L | 1 |
| Staszewski, S | 1 |
| Gendelman, HE; Lanier, ER; Limoges, J; McClernon, DR; Persidsky, Y; Poluektova, L; Rasmussen, J; Ratanasuwan, W; Zelivyanskaya, M | 1 |
| Ait-Khaled, M; Cutrell, A; Griffin, P; Harrigan, R; Katlama, C; Mesogiti, D; Miller, V; Pearce, G; Staszewski, S; Stone, C; Tisdale, M | 1 |
| Bloor, S; Griffin, P; Harrigan, PR; Kemp, S; Larder, B; Nájera, I; Stone, C; Tisdale, M | 1 |
| Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
| Babiker, A; de Rossi, A; Gibb, DM; Grosch-Woerner, I; Klein, N; Newberry, A | 1 |
| Burger, DM; Hoetelmans, RM; Jurriaans, S; Lange, JM; Portegies, P; Prins, JM; Sommadossi, JP; Turner-Foisy, ML; van Praag, RM; Weverling, GJ; Zhou, XJ | 1 |
| Lou, Y; McDowell, JA; Stein, DS; Symonds, WS | 1 |
| Binley, JM; Clas, B; Hurley, A; Ketas, T; Little, S; Markowitz, M; Moore, JP; Richman, D; Schiller, D; Trkola, A | 1 |
| Dechant, C; Goldwich, A; Grunke, M; Harrer, T; Kalden, JR; Kasten, S; Rascu, A; Schmitt, M | 1 |
| Degen, O; Stellbrink, HJ; van Lunzen, J | 1 |
| Church, JA; Cutrell, A; Emmanuel, P; Hetherington, S; Mitchell, C; Nelson, RP; Richardson, CG; Sáez-Llorens, X; Sleasman, J; Spreen, W; Van Dyke, R; Wiznia, A | 1 |
| Kerr, C | 1 |
| Bellman, PC; Fisher, RL; Henry, K; Liao, Q; Norris, D; Ross, LL; Shaefer, MS; Wallace, RJ | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Goh, LE; Grey, P; Kaufmann, GR; Smith, D; Suzuki, K; Zaunders, JJ | 1 |
| Thompson, CA | 1 |
| Brotas, V; Cooper, D; Cutrell, A; Gathe, J; Hammer, SM; Hetherington, S; Hicks, C; Isaacs, R; Johnson, M; Keiser, P; Montaner, J; Raffi, F; Spreen, W; Staszewski, S; Steel, H; Thorborn, D; Tortell, S | 1 |
| Loveday, C | 1 |
| Allsup, TL; Hutman, HW; Lou, Y; Mahony, WB; Otto, VR; Thompson, NF; Yuen, GJ | 1 |
| Crémieux, AC; Demarles, D; Gillotin, C; Katlama, C; Raffi, F; Yuen, GJ | 1 |
| Caldwell, P; Furlan, S; Ho, D; Hurley, A; Johnson, J; Kost, RG; Markowitz, M; Smiley, L; Talal, A; Vesanen, M; Zhang, L | 1 |
| Hanna, L | 1 |
| Bentata, M; David, F; Delfraissy, JF; Katlama, C; Lanier, ER; Mamet, JP; Massip, P; Rozenbaum, W; Trepo, C; Vavro, C; Zucman, D | 1 |
| Angelini, E; Chêne, G; Clavel, F; Ferchal, F; Maillard, A; Molina, JM; Picard, V; Race, E | 1 |
| Bisset, LR; Böni, J; Hofmann-Lehmann, R; Lüthy, R; Lutz, H; Schüpbach, J | 1 |
| Blumoff, K; Garcia-Lerma, JG; Heneine, W; Nidtha, S; Weinstock, H | 1 |
| Korn, K; Schmidt, B; Schwingel, E; Walter, H; Werwein, M | 1 |
| Fischl, MA; Gao, H; Gensler, T; Graham, NM; Hernandez, JE; Hessenthaler, SM; Kirkland, LR; McClernon, DR; Paar, D; Pittman, G; Rosenzweig, JR; Tashima, KT | 1 |
| Bettendorf, D; Bucy, RP; Chan, E; Evans, T; Gonzalez, CJ; Landay, AL; Phair, JP; Schmitz, JL; Schnizlein-Bick, CT; Spritzler, J; Squires, KE | 1 |
| Andersson, J; Cooper, D; Goh, LE; Hoen, B; Janossy, G; Kinloch, S; Lampe, F; Perrin, L; Tilling, R; Tsoukas, C; Zaunders, J | 1 |
| Birkus, G; Cihlar, T; Greenwalt, DE; Hitchcock, MJ | 1 |
| Gazzard, BG; Moyle, GJ | 1 |
| de Wolf, F; Jurriaans, S; Lange, JM; Prins, JM; van Praag, RM; Wit, FW | 1 |
| Perrin, L | 1 |
| Battegay, M; Bernasconi, E; Bisset, LR; Chave, JP; Fischer, M; Furrer, H; Günthard, H; Hirschel, B; Howe, C; Lazzarin, A; Ledergerber, B; Opravil, M; Perrin, L; Vernazza, P; Weber, R; Yerly, S | 1 |
| Ait-Khaled, M; Clumeck, N; Cutrell, A; Fischl, MA; Gould, J; Greenberg, SB; Griffin, P; Lafon, S; Pearce, G; Peters, BS; Pulido, F; Rakik, A; Rubio, R; Spreen, W; Tisdale, M | 1 |
| Báez, C; Castaño, E; Castrejón, MM; Danehower, S; De Suman, O; Hetherington, S; Keller, A; Lanier, ER; McClernon, D; McCoig, C; Ramilo, O; Redondo, W; Richardson, C; Sáez-Llorens, X | 1 |
| Amin, J; Carr, A; Cooper, DA; Doong, N; Freund, J; Hoy, J; Hudson, J; Law, M; Martin, A; Smith, DE; Workman, C | 1 |
| Chemlal, K; de Truchis, P; Devidas, A; Force, G; Mamet, JP; Mechali, D; Praindhui, D; Pulik, M; Rouveix, E; Welker, Y | 1 |
| Almond, LM; Back, DJ; De Vries, C; Gould, J; Hoggard, PG; Kewn, S; Khoo, SH; Lou, Y; Maherbe, A; Sales, SD; Wood, R | 1 |
| Ait-Khaled, M; Babiker, AG; Compagnucci, A; De Rossi, A; Dunn, DT; Gibb, DM; Kaye, S; Loveday, C; Muñoz-Fernandez, MA; Pillay, D; Walker, AS | 1 |
| Bodasing, N; Fox, R; Gourlay, Y; Peters, SE; Seaton, RA | 1 |
| Everall, IP; Foster, R; Olajide, D | 1 |
| James, JS | 1 |
| Aquilina, C; Boué, F; Brun-Vezinet, F; Descamps, D; Goetschel, A; Lafeuillade, A; Livrozet, JM; Mamet, JP; Matheron, S; Thiaux, C; Troisvallets, D | 1 |
| Ibbotson, T; Perry, CM | 1 |
| Chakraborty, R; Cross, A; D'Agostino, A; Musoke, R; Palakudy, T | 1 |
| Herrmann, SE; James, IR; John, M; Mallal, SA; McKinnon, EJ; Moore, CB; Nolan, DA; White, AJ | 1 |
| Cuadrado Pastor, JM; Fernández Villalba, E; Pardo López, MA; Pérez Hervás, MP | 1 |
| Derse, D; Hill, SA; Lloyd, PA; McDonald, S; Wykoff, J | 1 |
| Hammond, EL; Mallal, SA; Mamotte, CD; Martin, AM; Nolan, DA; Pace, CS | 1 |
| Brown, LS; Crawford, KH; Farthing, CF; Goodwin, SD; Racine, J; Rawlings, MK; Scott, RC; Shaefer, MS; Thompson, MA; Tolson, JM; Williams, VC | 1 |
| Bouhour, D; Dumouchel-Champagne, H; Durupt, F; Ferry, T; Granier, P | 1 |
| Barber, RE; Lonergan, JT; Mathews, WC | 1 |
| Bellos, NC; Burnside, AE; Farthing, CE; Fischl, MA; Kauf, TL; Shaefer, MS; Thompson, MA; Wannamaker, PG; Williams, VC | 1 |
| Danner, SA; Gruzdev, B; Jurriaans, S; Lange, JM; Peeters, M; Prins, JM; Rakhmanova, A; Sankatsing, SU; van't Klooster, G; Weverling, GJ | 1 |
| Gallant, JE | 1 |
| Erbelding, EJ | 1 |
| Fisher, RL; Hernandez, JE; Hessenthaler, SM; Lonergan, JT; McComsey, GA; Sension, MG; Shalit, P; Ward, DJ; Williams, VC | 1 |
| Hernández-Quero, J; Martínez-Ramírez, M; Muñoz-Medina, L; Parra-Ruiz, J; Serrano-Falcón, C | 1 |
| Boyle, BA | 1 |
| Brew, BJ; Pemberton, L; Ray, J | 1 |
| Antoniou, T; Arbess, G; Gough, K; Yoong, D | 1 |
| Amin, J; Carr, A; Cooper, DA; Doong, N; Emery, S; Freund, J; Hoy, J; Martin, A; Ringland, C; Smith, DE; Workman, C | 1 |
| Acosta, EP; Gulick, RM; Klingman, KL; Kuritzkes, DR; Lustgarten, S; Maher, WE; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Shikuma, CM; Snyder, S; Squires, KE; Witt, MD | 1 |
| Cardiello, P; Cooper, DA; Emery, S; Juengprasert, N; Kroon, ED; Lange, JM; Phanuphak, P; Ratanasuwan, W; Ruxrungtham, K; Siangphoe, U; Srasuebkul, P; Tongtalung, M; Ubolyam, S; Ungsedhapand, C | 1 |
| Everall, IP; Kandanearatchi, A; Landau, S; Vyakarnam, A | 1 |
| File, TM; Fisher, RL; Hernandez, JE; Hessenthaler, SM; Lindsey, L; Lonergan, JT; McComsey, GA; Shalit, P; Ward, DJ; Williams, VC | 1 |
| Cahn, P; Carosi, G; Jordan, JC; Montroni, M; Pearce, G; Pharo, CE; Schechter, M; Smaill, F; Soto-Ramirez, L; Thomas, NE; Vibhagool, A | 1 |
| Cahn, P; Carosi, G; Jordan, JC; Pharo, CE; Schechter, M; Smaill, F; Soto-Ramirez, L; Steel, HM; Thomas, NE; Vibhagool, A | 1 |
| Cao, Y; McCoig, CC; Ramilo, O; Saavedra-Lozano, J; Vitetta, ES | 1 |
| Bates, M; Chappey, C; Clair, MS; Fisher, R; Lanier, ER; Parkin, N; Ross, L; Tisdale, M | 1 |
| De Luca, A; Di Giambenedetto, S | 1 |
| Maida, I; Nuñez, M; Soriano, V | 1 |
| Bonny, T; Brand, JD; Brothers, CH; Buendia, CB; Castillo, SA; DeJesus, E; Gerstoft, J; Hernandez, J; Herrera, G; Lanier, ER; Scott, TR; Teofilo, E | 1 |
| Ait-Khaled, M; Gibb, D; Givens, N; Griffin, P; Irlbeck, D; Lanier, ER; St Clair, M; Stone, C; Tisdale, M; Underwood, M; Walker, S | 1 |
| Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Lagathu, C; Lombès, A; Walker, UA | 1 |
| Baumann, D; Bernasconi, E; Blasko, M; Calmy, A; Chave, JP; Furrer, H; Ledergerber, B; Opravil, M; Perrin, L; Vernazza, P | 1 |
| Bower, M; Fisher, M; Gazzard, B; Johnson, M; Jones, R; Mandalia, S; Moyle, G; Nelson, M; Orkin, C; Stebbing, J | 1 |
| Gerber, JG; Wyles, DL | 1 |
| Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Marzocchetti, A; Pompucci, A; Scoppettuolo, G; Tumbarello, M; Vago, G | 1 |
| Cherry, CL; Fisher, RL; Hernandez, JE; Hessenthaler, SM; Hoppel, CL; Lonergan, JT; McComsey, GA; Paulsen, DM; Ross, LL; Ross, ST; Thompson, KA; White-Owen, C; Williams, VC | 1 |
| Ibarra Barrueta, O; Iglesias Lambarri, A; Illaro Uranga, A; Lertxundi Etxebarría, U; Martínez Bengoechea, MJ; Santos Ibáñez, A | 1 |
| Aarnoutse, RE; Burger, DM; Verweij-van Wissen, CP | 1 |
| del Rio, C | 1 |
| Cherry, CL; Hernandez, J; Lal, L; McComsey, G; McLean, CA; Ross, LL; Thompson, KA; Wesselingh, SL | 1 |
| Farthing, C; Guyer, B; Khanlou, H | 1 |
| D'Agostino, C; d'Ettorre, G; Lichtner, M; Massetti, AP; Mastroianni, CM; Vullo, V | 1 |
| Davis, EA; DeJesus, E; Hill-Zabala, C; Lang, J; Lanier, ER; Liao, Q; Markowitz, M; Shaefer, M | 1 |
| Bonjoch, A; Clotet, B; De la Torre, J; Galvez, J; Martínez, E; Miralles, C; Miranda, J; Muñoz-Moreno, JA; Paredes, R; Prieto, A; Videla, S; Vilades, C | 1 |
| Billaud, E; Bugnon, F; Cua, E; Cuzin, L; Dellamonica, P; Delpierre, C; Massip, P; Pugliese, P; Raffi, F | 1 |
| Bellón, JM; Berenguer, J; Camba, M; Flores, J; Gatell, JM; Hernández-Quero, J; Knobel, H; Miguélez, M; Pérez-Elías, MJ; Podzamczer, D; Resino, S; Rivas-González, P; Sala, M; Santos, I; Soriano, V | 1 |
| Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
| Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
| Bacheler, L; Koontz, D; Mellors, JW; Parikh, UM | 1 |
| Acosta, EP; Bastow, B; Carlson, M; Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, C; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
| Brothers, CH; Castillo, SA; Hernandez, JE | 1 |
| Cartledge, J; Churchill, D; Fakoya, A; Hay, P; Johnson, M; Leen, C; Moyle, GJ; Murphy, M; Reilly, G; Sabin, CA; Scullard, G; Wilkins, E | 1 |
| Antonelli, G; Baranello, C; Bellomi, F; Falasca, F; Focher, F; Morgan, J; Pagnotti, P; Pierangeli, A; Schuetz, JD; Turriziani, O | 1 |
| Mellors, JW; Parikh, UM; Sheen, CW; Sluis-Cremer, N; Torres, PS; Zelina, S | 1 |
| Bartlett, MG; Lewis, SR; White, CA | 1 |
| Feinberg, J | 1 |
| Neal, EF; Poston, PA; Robbins, BL; Rodman, JH; Slaughter, C | 1 |
| Bastow, B; Glesby, MJ; Gulick, RM; Kuritzkes, DR; Meyer, WA; Ribaudo, HJ; Shikuma, CM; Tashima, KT; Webb, N; Yang, Y | 1 |
| Keiser, P; Nassar, N | 1 |
| Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Meyer, WA; Reichman, R; Ribaudo, HJ; Riddler, SA; Santana, J; Shikuma, C; Squires, KE | 1 |
| Elmquist, WF; Giri, N; Pan, G | 1 |
| Butler, K; Candeias, F; Castelli-Gattinara, G; Compagnucci, A; de Rossi, A; Della Negra, M; Feiterna-Sperling, C; Giaquinto, C; Gibb, DM; Green, H; Harper, L; Levy, J; Pillay, D; Saidi, Y; Walker, AS; Wintergerst, U | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Enejosa, J; Hinkle, J; Kearney, BP; Ramanathan, S; Shen, G | 1 |
| Elmquist, WF; Giri, N; Pan, G; Shaik, N | 1 |
| Doerr, HW; Staszewski, S; Stürmer, M | 1 |
| Boom, WH; Charlebois, ED; Havlir, DV; Kayanja, HK; Lin, R; Mayanja-Kizza, H; Mugerwa, RD; Srikantiah, P; Walusimbi, MN; Whalen, CC | 1 |
| Gulick, RM; Kuritzkes, DR; Ribaudo, HJ | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Cavassini, M; Furrer, H; Günthard, H; Hirschel, B; Opravil, M; Vernazza, P; von Wyl, V; Wolbers, M; Yerly, S | 1 |
| Díaz-Curiel, M; Fernández-Guerrero, ML; García-Delgado, R; Górgolas, M; Goyenechea, A; Rivas, P | 1 |
| Elmquist, WF; Giri, N; Kitagaki, S; Miyakoshi, N; Mukai, C; Pan, G; Shaik, N; Terasaki, T | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Galindo, MJ; Iribarren, J; Llibre, JM; Martinez-Picado, J; Negredo, E; Pérez-Alvarez, N; Schapiro, J | 1 |
| Gibert, CL; Grunfeld, C; Peng, G; Sharma, S; Shlay, JC | 1 |
| Haas, RH; Naviaux, RK; Saitoh, A; Salva, NG; Spector, SA; Wong, JK | 1 |
| Cortes, C; Domingo, P; Ferrer, E; Gatell, JM; Gutierrez, M; Leon, A; Niubo, J; Pedrol, E; Podzamczer, D; Puig, T; Sanchez, P; Veloso, S | 1 |
| Bánhegyi, D; Bannister, WP; Chiesi, A; Friis-Møller, N; Gargalianos, P; Kirk, O; Lundgren, JD; Mocroft, A; van Lunzen, J; Viard, JP | 1 |
| Atté, EF; Rasschaert, F; Reid, T; van Griensven, J; Zachariah, R | 1 |
| Czauski, G; de Araújo Castro, GF; de Araújo Soares, RM; de Souza, IP; Kneipp, L; Pomarico, L; Portela, MB | 1 |
| Arndt, P; Clotet, B; Erkizia, I; Gorboulev, V; Koepsell, H; Martinez-Picado, J; Minuesa, G; Molina-Arcas, M; Pastor-Anglada, M; Volk, C | 1 |
| Ishikawa, H; Kaneko, S; Katayama, M; Matsuda, Y; Miyaji, K; Suzuki, K; Takamatsu, K | 1 |
| Berzins, B; Evans, S; Forand, J; Hafner, R; Murphy, R; Owens, S; Shevitz, A; Tashima, K; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Dauer, B; Gute, P; Khaykin, P; Klauke, S; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Benn, P; Cartledge, J; Edwards, SG; Linney, A; Moyle, G; Reilly, G; Ruff, C; Sabin, CA; Sauret-Jackson, V | 1 |
| Cohen, C; Dejesus, E; Elion, R; Gathe, JC; Ha, B; Hsu, RK; Lanier, R; Paulsen, D; Redfield, RR; Ross, L; Yau, L | 1 |
| Benfield, T; Kjaer, A; Kofoed, K; Kristoffersen, US; Kronborg, G; Lebech, AM | 1 |
| Burke, A; Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Katundu, P; Kityo, C; Lyagoba, F; McCormick, A; Munderi, P; Ndembi, N; Pillay, D; Robertson, V; Walker, AS; Yirrell, DL | 1 |
| Asahchop, EL; Brenner, BG; Moisi, D; Ntemgwa, M; Toni, TA; Wainberg, MA | 1 |
| Bartlett, JA; Crump, JA; Kiwera, RA; Moon, AM; Ole-Nguyaine, S; Ramadhani, HO; Shao, HJ; Shao, JF; Thielman, NM; Uiso, LO; Woods, CW | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Babiker, AG; Darbyshire, JH; Gibb, DM; Gilks, CF; Grosskurth, H; Kityo, C; Mugyenyi, P; Munderi, P; Reid, A; Ssali, F; Walker, AS | 1 |
| Butini, L; Cirioni, O; Costantini, A; Giacometti, A; Montroni, M; Scalise, G | 1 |
| Bravenboer, B; Gisolf, EH; Groeneveld, PH; Hoepelman, AI; Koopmans, PP; Langebeek, N; Legrand, JC; Mulder, PG; Richter, C; Sprenger, HG; Ten Kate, RW; Ten Napel, CH; van der Werf, TS; Van Kasteren, ME; Vriesendorp, R | 1 |
| Avihingsanon, A; Belloso, WH; Boesecke, C; Cooper, DA; Duncombe, C; Emery, S; Gazzard, B; Li, L; Molina, JM; Petoumenos, K; Puls, RL; Srasuebkul, P | 1 |
| Curran, A; Ribera, E | 1 |
| Bacheler, L; Dunn, DT; Gilks, C; Goodall, RL; Kaleebu, P; Kityo, C; Munderi, P; Pillay, D; Ranopa, M; Van Houtte, M | 1 |
| Moreno, V; Valencia, ME | 1 |
| Boom, WH; Charlebois, E; Havlir, DV; Lin, R; Mayanja-Kizza, H; Mugerwa, RD; Mugyenyi, P; Mupere, E; Nanteza, MW; Srikantiah, P; Whalen, CC | 1 |
| Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kityo, C; Mambule, I; Munderi, P; Reid, A; Ssali, F; Stöhr, W; Walker, AS | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| Adkison, KK; Bakeera-Kitaka, S; Burger, DM; Gibb, DM; Kasirye, P; Kekitiinwa, A; Kendall, L; Mhute, T; Nahirya-Ntege, P; Snowden, W; Ssenyonga, M; Tumusiime, C; Walker, AS | 1 |
| Fessel, WJ; Israelski, D; Kagan, R; Kaufman, D; Melikian, GL; Rhee, SY; Robbins, GK; Shafer, RW; Taylor, J; Towner, W; Troia-Cancio, PV; Zolopa, A | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Andriamanantena, D; Ficko, C; Flateau, C; Rapp, C; Reggad, A | 1 |
| Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM | 1 |
| Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS | 1 |
| Antinori, A; Bansi, L; Boumis, E; Callegaro, A; Ceccherini-Silberstein, F; Dunn, D; Fearnhill, E; Forbici, F; Francisci, D; Maggiolo, F; Mussini, C; Nicastri, E; Palamara, G; Perno, CF; Sabin, C; Santoro, MM; Zazzi, M; Zoncada, A | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G | 1 |
| Chin, BS; Kim, HS; Shin, HS | 1 |
| Arnoczy, G; Campbell, T; Fichtenbaum, CJ; Ha, B; Hicks, C; Koletar, S; Massengale, K; McComsey, GA; Sax, P; Stein, JH; Taiwo, B; Tebas, P; Walsh, K; Wohl, DA | 1 |
| Gisolf, EH; Langebeek, N; Legrand, J; Nieuwkerk, PT; Reiss, P; Richter, C; Sprangers, MA; Sprenger, HG | 1 |
| Gilks, CF; Goodall, RL; Gupta, RK; Kaleebu, P; Kityo, C; Lyagoba, F; Mugarura, L; Munderi, P; Pillay, D; Ranopa, M | 1 |
| Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Kasirye, R; Kityo, C; Mambule, I; Mugyenyi, P; Pillay, D; Walker, AS | 1 |
| Abongomera, G; Arach, B; Asiimwe, AR; Cook, A; Gibb, DM; Kabamba, D; Kayiwa, J; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; Komunyena, J; Mirembe, G; Mulenga, V; Musiime, V; Nansubuga, C; Walker, SA; Wavamunno, P; Zangata, D | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Borok, M; Campbell, TB; Erlandson, KM; Fiorillo, S; Gudza, I; Gwanzura, L; Ndemera, B; Schooley, RT | 1 |
| Blanche, S; Flynn, P; Giaquinto, C; Kakuda, TN; Komar, S; Lathouwers, E; Noguera-Julian, A; Opsomer, M; Van de Casteele, T; Welch, S | 1 |
| Bierman, W; Bravenboer, B; Gisolf, E; Groeneveld, P; Hoepelman, AI; Koopmans, PP; Langebeek, N; Legrand, JC; Mulder, PG; Richter, C; Sprenger, HG; Ten Kate, RW; Ten Napel, CH; van der Werf, Ts; Vriesendorp, R | 1 |
| Avi, R; Huik, K; Jõgeda, EL; Kallas, E; Karki, T; Lutsar, I; Margus, T; Pauskar, M | 1 |
| Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS | 1 |
| Arends, J; Chene, G; Cosin, J; Dabis, F; Daikos, G; de Wit, S; Mallolas, J; Montforte, Ad; Mussini, C; Peters, L; Raben, D; Rockstroh, J; Smit, C; Zangerle, R; Zinkernagel, A | 1 |
| Gorantla, S; Lu, Y; Makarov, E; Senanayake, TH; Vinogradov, SV; Warren, G | 1 |
| Goryaeva, MP; Gulyaeva, SS; Minaeva, SV; Moshkovich, GF; Tichonova, EV; Varlova, LW | 1 |
| Chen, X; Cheng, Y; Guan, S; Han, L; Liu, Y; Wang, C | 1 |
| Ananworanich, J; Chokephaibulkit, K; Do, VC; Kerr, SJ; Kosalaraksa, P; Kurniati, N; Nguyen, LV; Prasitsuebsai, W; Singtoroj, T; Sohn, AH; Sudjaritruk, T; Teeraananchai, S; Truong, KH | 1 |
| Divi, RL; Gibbons, AT; Liu, Y; Poirier, MC; Shide, ED; Shim Park, E; Woodward, RA | 1 |
| Abach, J; Abongomera, G; Chabala, C; Colebunders, R; Cook, A; Gibb, DM; Kekitiinwa, A; Kityo, C; Lamorde, M; Mulenga, V; Musiime, V; Thomason, M; Walker, AS | 1 |
| Dunn, DT; Gilks, C; Goodall, RL; Gupta, RK; Kaleebu, P; Kityo, C; Mugarura, L; Munderi, P; Nkurunziza, P; Pattery, T; Pillay, D | 1 |
| Boulle, A; Cohen, K; Davies, MA; de Waal, R; Fortuin-de Smidt, M; Igumbor, EU; Maartens, G; Stinson, K; Technau, KG | 1 |
| Barrow, G; Camacho, R; Carmona, S; Grant, PM; Gupta, RK; Hamers, RL; Harrigan, PR; Jordan, MR; Kantor, R; Katzenstein, DA; Kuritzkes, DR; Maldarelli, F; Otelea, D; Paredes, R; Schapiro, JM; Shafer, RW; Tzou, PL; van Zyl, G; Wallis, CL | 1 |
| Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL | 1 |
| Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
| Bailão, E; Cardoso, CG; Chen-Chen, L; Cunha, KS; de Jesus Silva Carvalho, C; de Moraes Filho, AV; Spanó, MA; Véras, JH | 1 |
| Brown, K; Cotton, MF; Frigati, LJ; Githinji, L; Gray, D; Hoare, J; Mahtab, S; Myer, L; Nourse, P; Stein, DJ; Zar, HJ; Zühlke, L | 1 |
| Mega, TA; Negera, GZ; Usamo, FB | 1 |
| Batra, H; Chawla, H; Das, BK; Hussain, AW; Kabra, SK; Katpara, S; Kumar, S; Lodha, R; Luthra, K; Singh, R; Singh, S | 1 |
14 review(s) available for zidovudine and abacavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Coming therapies: abacavir.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.
Topics: Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Antiretroviral therapy-induced psychosis: case report and brief review of the literature.
Topics: Adult; Antipsychotic Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Female; Hallucinations; HIV Seropositivity; Humans; Lamivudine; Nevirapine; Psychoses, Substance-Induced; Zidovudine | 2003 |
Lamivudine/zidovudine/abacavir: triple combination tablet.
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Treatment Outcome; Zidovudine | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Treatment Outcome; Zidovudine | 2007 |
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2007 |
From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.
Topics: Adenine; Adipose Tissue; Body Composition; Dideoxynucleosides; Drug Substitution; Humans; Metabolism; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zidovudine | 2011 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2013 |
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Maintenance Chemotherapy; Middle Aged; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2013 |
78 trial(s) available for zidovudine and abacavir
| Article | Year |
|---|---|
A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; HIV-1; Humans; Lamivudine; RNA, Viral; Time Factors; Viral Load; Zidovudine | 1998 |
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV-1; Humans; Male; RNA, Viral; Time Factors; Viral Load; Zidovudine | 1998 |
Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Zidovudine | 1999 |
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
Topics: Cohort Studies; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Zidovudine | 2000 |
Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients.
Topics: Acquired Immunodeficiency Syndrome; Alleles; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Resistance, Microbial; Female; HIV-1; Humans; Lamivudine; Male; Receptors, CCR5; Zidovudine | 2000 |
A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Confidence Intervals; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Growth; HIV-1; Humans; Infant; Lamivudine; Male; RNA, Viral; Zidovudine | 2001 |
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2001 |
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Microbial; Female; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Indinavir; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Survival Analysis; Therapeutic Equivalency; Viral Load; Zidovudine | 2001 |
Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
Topics: Absorption; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Eating; Fasting; Female; Half-Life; Humans; Lamivudine; Male; Mass Spectrometry; Middle Aged; Reverse Transcriptase Inhibitors; Therapeutic Equivalency; Zidovudine | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Half-Life; HIV Infections; HIV-1; Humans; Lamivudine; Male; Metabolic Clearance Rate; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2001 |
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Dideoxynucleosides; Digestive System; Drug Synergism; Ethnicity; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Subsets; Male; Pregnancy; Research Design; RNA, Viral; Sulfonamides; Treatment Refusal; Zidovudine | 2001 |
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Time Factors; Zidovudine | 2001 |
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
Triple nuke therapy--results after one year.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Zidovudine | 2002 |
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclopropanes; Didanosine; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2002 |
Therapeutic vaccination in primary HIV infection, the Quest trial.
Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Defective Viruses; Dideoxynucleosides; Furans; HIV Infections; Humans; Immunotherapy, Active; Lamivudine; Lymphocyte Count; Sulfonamides; T-Lymphocyte Subsets; Vaccination; Vaccinia virus; Viral Load; Viral Vaccines; Viremia; Zidovudine | 2002 |
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV-1; Humans; Lamivudine; Lipids; Male; Prospective Studies; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2002 |
Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Zidovudine | 2002 |
Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV-1; Humans; Infant; Lamivudine; RNA, Viral; Statistics, Nonparametric; Viral Load; Zidovudine | 2002 |
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Body Composition; Dideoxynucleosides; Female; HIV Infections; Humans; Lipids; Lipodystrophy; Male; Middle Aged; Quality of Life; Reverse Transcriptase Inhibitors; Stavudine; Tomography, X-Ray Computed; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions; Drug Resistance, Viral; Female; HIV Infections; Humans; Hydroxyurea; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Nevirapine; Nucleosides; Phosphorylation; Reverse Transcriptase Inhibitors; Zidovudine | 2002 |
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV-1; Humans; Lamivudine; Nelfinavir; Phenotype; RNA, Viral; Zidovudine | 2002 |
Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Zidovudine | 2003 |
Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
Topics: Adult; Body Composition; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Stavudine; Zidovudine | 2003 |
Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.
Topics: Adipocytes; Adipose Tissue; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cell Differentiation; Dideoxynucleosides; DNA, Mitochondrial; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mitochondria; Mitochondrial Proteins; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Messenger; Stavudine; Zidovudine | 2003 |
Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Patient Education as Topic; RNA, Viral; Zidovudine | 2003 |
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Chemistry, Pharmaceutical; Confidence Intervals; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Zidovudine | 2003 |
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2003 |
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; HIV; HIV Infections; HIV-1; Humans; Lipodystrophy; Male; Middle Aged; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2004 |
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Topics: Absorptiometry, Photon; Adipose Tissue; Anti-HIV Agents; Body Composition; Bone Density; Dideoxynucleosides; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2004 |
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; RNA, Viral; Stavudine; Thailand; Time Factors; Zidovudine | 2004 |
Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Lactates; Male; Middle Aged; Recurrence; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2004 |
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; RNA; Surveys and Questionnaires; Therapeutic Equivalency; Treatment Outcome; Zidovudine | 2004 |
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome; Zidovudine | 2004 |
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Viral; Zidovudine | 2004 |
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients.
Topics: CD4 Lymphocyte Count; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; RNA, Viral; Viral Load; Zidovudine | 2005 |
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; RNA, Viral; Zidovudine | 2005 |
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Patient Compliance; Patient Satisfaction; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2005 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Messenger; Viral Load; Zidovudine | 2006 |
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Biomarkers; Body Fat Distribution; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2006 |
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Body Composition; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Insulin Resistance; Lactic Acid; Lamivudine; Lipids; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2007 |
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Regression Analysis; RNA, Viral; Time Factors; Zidovudine | 2007 |
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Viral; Follow-Up Studies; Growth; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2007 |
A comparison of three initial antiretroviral AIDS regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2007 |
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; Zidovudine | 2008 |
Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.
Topics: Adult; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Subcutaneous Fat; Zidovudine | 2008 |
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Endpoint Determination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Spain; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Intra-Abdominal Fat; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Radiography, Abdominal; Stavudine; Thigh; Viral Load; Zidovudine | 2009 |
Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Topics: Absorptiometry, Photon; Adenine; Adult; Aged; Body Composition; Cheek; Dideoxynucleosides; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Organophosphonates; Quality of Life; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2009 |
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Mutation; Nevirapine; RNA, Viral; Uganda; Viral Load; Zidovudine | 2010 |
Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Male; Pilot Projects; Tanzania; Tuberculosis; Viral Load; Zidovudine | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Uganda; Viral Load; Zidovudine | 2010 |
Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2010 |
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2010 |
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; RNA, Viral; Viral Load; Zidovudine | 2011 |
A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Survival Analysis; Treatment Outcome; Tuberculosis, Pulmonary; Uganda; Young Adult; Zidovudine | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Glomerulus; Lamivudine; Male; Nevirapine; Organophosphonates; Risk Factors; Tenofovir; Time Factors; Zidovudine | 2011 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Infant; Lactation; Lamivudine; Lopinavir; Middle Aged; Milk, Human; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2013 |
A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Netherlands; Odds Ratio; Patient Satisfaction; Quality of Life; Ritonavir; Zidovudine | 2014 |
High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Nevirapine; Viral Load; Viremia; Zidovudine | 2014 |
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Probability; Retrospective Studies; RNA, Viral; Tenofovir; Uganda; Viral Load; Zidovudine | 2014 |
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Topics: Anthropometry; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipid Metabolism; Lipodystrophy; Lipoproteins, HDL; Lipoproteins, LDL; Male; Nevirapine; Stavudine; Triglycerides; Viral Load; Zidovudine | 2014 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Dideoxynucleosides; Disease Progression; Female; Herpesvirus 8, Human; HIV-1; Humans; Lamivudine; Male; Middle Aged; Odds Ratio; Pilot Projects; Prospective Studies; RNA, Viral; Sarcoma, Kaposi; Survival Analysis; Treatment Outcome; Vitamin D; Vitamin D Deficiency; Zidovudine; Zimbabwe | 2014 |
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Topics: Adolescent; Anemia; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Nausea; Neutropenia; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Time Factors; Viral Load; Vomiting; Zidovudine | 2014 |
A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Topics: Adult; Aged; Anti-HIV Agents; Belgium; CD4 Lymphocyte Count; Clinical Protocols; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Netherlands; Prospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2015 |
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine; Tablets; Uganda; Zambia; Zidovudine | 2016 |
134 other study(ies) available for zidovudine and abacavir
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase.
Topics: Adenine; Amino Acid Substitution; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2007 |
Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.
Topics: Anti-HIV Agents; HeLa Cells; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Reverse Transcriptase Inhibitors; Zidovudine | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Design, synthesis, and anti-HIV activity of 4'-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cell Line, Tumor; Drug Design; HIV Reverse Transcriptase; Humans; Models, Molecular; Molecular Structure; Nucleosides; Organophosphonates; Prodrugs; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides.
Topics: Anti-HIV Agents; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Molecular Structure; Nucleosides; Prodrugs; Structure-Activity Relationship | 2013 |
Ionic derivatives of betulinic acid exhibit antiviral activity against herpes simplex virus type-2 (HSV-2), but not HIV-1 reverse transcriptase.
Topics: Acyclovir; Animals; Antiviral Agents; Betulinic Acid; Chlorocebus aethiops; Herpesvirus 2, Human; HIV Reverse Transcriptase; HIV-1; Humans; Pentacyclic Triterpenes; Triterpenes; Vero Cells; Virus Replication | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Virus Replication; Zidovudine | 1998 |
A Na(+)-dependent nucleoside transporter in microglia.
Topics: Adenosine; Animals; Carrier Proteins; Cell Size; Cells, Cultured; Cytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Guanosine; Membrane Proteins; Microglia; Nucleic Acid Probes; Nucleoside Transport Proteins; Rats; Rats, Wistar; Sodium; Thymidine; Time Factors; Uridine; Zidovudine | 2000 |
Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.
Topics: AIDS Dementia Complex; Animals; Cells, Cultured; Didanosine; Dideoxynucleosides; Disease Models, Animal; HIV-1; Humans; Lamivudine; Male; Mice; Mice, SCID; Monocytes; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zidovudine | 2000 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Codon; Dideoxynucleosides; Drug Resistance; Drug Therapy, Combination; HIV Reverse Transcriptase; Humans; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2000 |
[First HIV triple therapy with one tablet].
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2000 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Disease Reservoirs; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Stavudine; Viral Load; Zidovudine | 2000 |
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Furans; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Neutralization Tests; Ritonavir; Sulfonamides; Zidovudine | 2000 |
Intensification of background antiretroviral therapy with abacavir during low-level failure may restore optimal suppression.
Topics: Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2000 |
Trizivir on the market.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 2001 |
Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Epstein-Barr Virus Infections; Flow Cytometry; Furans; Genotype; HIV Infections; HIV-1; Humans; Immunoglobulin M; Lamivudine; Longitudinal Studies; Male; Proto-Oncogene Proteins c-bcl-2; Receptors, CCR5; Sulfonamides; Time Factors; Zidovudine | 2001 |
Triple-drug tablet approved for HIV infection.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Dideoxynucleosides; Drug Combinations; Drug Labeling; HIV Infections; Humans; Lamivudine; Tablets; Zidovudine | 2001 |
New drugs: amprenavir and abacavir.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1998 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine | 1998 |
A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Lamivudine; Lipodystrophy; Oxazines; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1998 |
A new HAART on the horizon says the proof is in the potency.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; Patient Compliance; Pregnancy; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Nukes alone.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; France; HIV Infections; Humans; Lamivudine; Zidovudine | 1999 |
Choosing which nuke to use first.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
[Acceptance of antiretroviral therapy. HIV-infected patients assess convenient triple combination].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Patient Acceptance of Health Care; Patient Compliance; Zidovudine | 2001 |
Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication.
Topics: Animals; Anti-HIV Agents; Cats; Cell Line; Dideoxynucleosides; Drug Synergism; Drug Therapy, Combination; Feline Acquired Immunodeficiency Syndrome; Humans; Hydroxyurea; Immunodeficiency Virus, Feline; Kidney; Lamivudine; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 2002 |
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
Topics: Anti-HIV Agents; Base Sequence; Didanosine; Dideoxynucleosides; DNA, Viral; Drug Resistance, Viral; Evolution, Molecular; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis; Recombination, Genetic; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zalcitabine; Zidovudine | 2001 |
Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo.
Topics: Algorithms; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Microbial; Gene Frequency; Genotype; HIV; Humans; Lamivudine; Microbial Sensitivity Tests; Zidovudine | 2002 |
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates; CD48 Antigen; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphocyte Count; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Treatment Outcome; Viral Load; Viremia; Zidovudine | 2002 |
Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Anti-HIV Agents; Antigens, CD34; Cell Line; Didanosine; Dideoxynucleosides; Epithelial Cells; Hematopoietic Stem Cells; Humans; Kidney Tubules, Proximal; Liver; Muscle, Skeletal; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Tumor Cells, Cultured; Zalcitabine; Zidovudine | 2002 |
Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dideoxynucleosides; Drug Evaluation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; London; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Viremia; Zidovudine | 2002 |
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Follow-Up Studies; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Virus Replication; Zidovudine | 2002 |
Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Viral Load; Zidovudine | 2003 |
FDA notifications. Product tampering labels Ziagen as Combivir.
Topics: Acquired Immunodeficiency Syndrome; Dideoxynucleosides; Drug Combinations; Drug Labeling; Humans; Lamivudine; United States; United States Food and Drug Administration; Zidovudine | 2002 |
Abacavir arm stopped in clinical trial.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Viral Load; Zidovudine | 2003 |
Management of severely immunocompromised human immunodeficiency virus type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Dideoxynucleosides; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Salvage Therapy; Zidovudine | 2003 |
[Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone].
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Humans; Lamivudine; Male; Methadone; Opioid-Related Disorders; Reverse Transcriptase Inhibitors; Substance Withdrawal Syndrome; Treatment Outcome; Zidovudine | 2003 |
Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Cell Line; Dideoxynucleosides; Human T-lymphotropic virus 1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Virus Replication; Zalcitabine; Zidovudine | 2003 |
[Hypersensitive reaction to abacavir or syphilitic hepatitis?].
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Ethylenediamines; HIV Seropositivity; Humans; Lamivudine; Male; Syphilis; Zidovudine | 2003 |
Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
Topics: Acidosis, Lactic; Adult; Alanine Transaminase; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Zidovudine | 2003 |
AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Abandon Trizivir when it's working well? A rebuttal.
Topics: Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Comment: Reasons for early abacavir discontinuation in HIV-infected patients.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Treatment Refusal; Zidovudine | 2004 |
Can the peripheral blood monocyte count be used as a marker of CSF resistance to antiretroviral drugs?
Topics: Anti-HIV Agents; Biomarkers; Buffers; Culture Media; Dideoxynucleosides; Drug Resistance, Viral; HIV; HIV Infections; Humans; In Vitro Techniques; Leukocyte Count; Monocytes; Stavudine; Zidovudine | 2004 |
Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.
Topics: Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions; Epilepsy, Complex Partial; HIV Infections; Humans; Lamivudine; Male; Valproic Acid; Zidovudine | 2004 |
Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors.
Topics: AIDS Dementia Complex; Antiretroviral Therapy, Highly Active; Brain; Dideoxynucleosides; HIV-1; Humans; In Vitro Techniques; Reverse Transcriptase Inhibitors; Stavudine; Virus Replication; Zidovudine | 2004 |
Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.
Topics: Anti-HIV Agents; Cells, Cultured; Dideoxynucleosides; Drug Evaluation, Preclinical; HIV Core Protein p24; HIV Infections; Humans; Immunotoxins; Lamivudine; Phytohemagglutinins; Receptors, Interleukin-2; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
Topics: Adenine; Algorithms; Anti-HIV Agents; Databases, Genetic; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV; HIV Infections; Humans; Mutation; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Genes, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Point Mutation; Retrospective Studies; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.
Topics: 3T3-L1 Cells; Adenine; Adipocytes; Animals; Apoptosis; Cell Differentiation; Didanosine; Dideoxynucleosides; HIV-1; HIV-Associated Lipodystrophy Syndrome; Lamivudine; Lipid Metabolism; Mice; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Zidovudine | 2004 |
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Failure; Zidovudine | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity?
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Brain; CD4 Lymphocyte Count; Cidofovir; Cytosine; Dideoxynucleosides; Encephalitis; False Negative Reactions; Fatal Outcome; Humans; Immunocompromised Host; Indinavir; JC Virus; Lamivudine; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Organophosphonates; Substance Abuse, Intravenous; Time Factors; Virus Activation; Zidovudine | 2004 |
Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
Topics: Adipocytes; Adipose Tissue; Adult; Apoptosis; Dideoxynucleosides; DNA, Mitochondrial; Electron Transport; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Muscle, Skeletal; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2005 |
[Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Costs and Cost Analysis; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Patient Compliance; Retrospective Studies; Zidovudine | 2004 |
Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Drug Stability; HIV; HIV Infections; Humans; Lamivudine; Quality Control; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stavudine; Zidovudine | 2005 |
Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.
Topics: Adipocytes; Adipose Tissue; Adult; Anti-HIV Agents; Apoptosis; Biopsy; Dideoxynucleosides; DNA; DNA Fragmentation; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; In Situ Nick-End Labeling; Male; Middle Aged; Stavudine; Zidovudine | 2005 |
Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Hypersensitivity; Lamivudine; Male; Patient Compliance; Retrospective Studies; Spain; Treatment Failure; Zidovudine | 2006 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Arginine; Didanosine; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genotype; HIV Reverse Transcriptase; HIV-1; Humans; Lysine; Organophosphonates; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Zalcitabine; Zidovudine | 2006 |
Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Controlled Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Oxazines; Prospective Studies; Time Factors; Treatment Outcome; Zidovudine | 2006 |
The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine Kinase; Dideoxynucleosides; Drug Resistance, Neoplasm; Humans; Lamivudine; Leukemia, Lymphoid; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phenotype; T-Lymphocytes; Thymidine Kinase; Zidovudine | 2006 |
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides; Drug Resistance, Multiple, Viral; Genotype; Glutamic Acid; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lysine; Mutagenesis, Site-Directed; Organophosphonates; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir; Thymine Nucleotides; Zidovudine | 2007 |
Simultaneous determination of abacavir and zidovudine from rat tissues using HPLC with ultraviolet detection.
Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Dideoxynucleosides; Female; Pregnancy; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Spectrophotometry, Ultraviolet; Zidovudine | 2007 |
Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2006 |
Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Phosphates; Reference Standards; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Zidovudine | 2007 |
Anti-HIV agents. Abacavir--as good as AZT?
Topics: Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Cell Membrane Permeability; Dideoxynucleosides; Dogs; Dose-Response Relationship, Drug; Reverse Transcriptase Inhibitors; Tetrahydroisoquinolines; Time Factors; Transfection; Zidovudine | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir.
Topics: Adolescent; Adult; Confidence Intervals; Cross-Over Studies; Didanosine; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Stavudine; Zidovudine | 2007 |
P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
Topics: Acridines; Adenosine Triphosphatases; Animals; Anti-HIV Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Brain; Cell Line; Cell Membrane; Dibenzocycloheptenes; Dideoxynucleosides; Humans; Mice; Mice, Inbred Strains; Mice, Knockout; Molecular Structure; Quinolines; Reverse Transcriptase Inhibitors; Tetrahydroisoquinolines; Vinblastine; Zidovudine | 2007 |
Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Tuberculosis, Pulmonary; Zidovudine | 2007 |
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Genes, MDR; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Reverse Transcriptase Inhibitors; RNA, Viral; Switzerland; Treatment Failure; Viral Load; Zidovudine | 2007 |
Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Case-Control Studies; Dideoxynucleosides; Femur Neck; HIV Infections; Humans; Lamivudine; Lopinavir; Lumbar Vertebrae; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; Zidovudine | 2008 |
Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Cell Line; Chromatography, High Pressure Liquid; Dideoxynucleosides; Mice; Mice, Knockout; Reverse Transcriptase Inhibitors; Tissue Distribution; Zidovudine | 2008 |
New formulations approved for children.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Child; Child, Preschool; Dideoxynucleosides; Drug Approval; Drug Combinations; European Union; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 2008 |
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Thymidine; Viral Load; Zidovudine | 2008 |
Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells.
Topics: Cell Proliferation; Cells, Cultured; Dideoxynucleosides; DNA, Mitochondrial; Humans; Lamivudine; Muscle Fibers, Skeletal; Muscle, Skeletal; Myoblasts; Nucleosides; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Mitochondrial; Stavudine; Zidovudine | 2008 |
Incidence of abacavir hypersensitivity reactions in euroSIDA.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Poisson Distribution; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2008 |
Weight evolution in HIV-1 infected women in Rwanda after stavudine substitution due to lipoatrophy: comparison of zidovudine with tenofovir/abacavir.
Topics: Adenine; Adult; Anti-HIV Agents; Body Weight; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Organophosphonates; Rwanda; Stavudine; Tenofovir; Treatment Outcome; Weight Loss; Zidovudine | 2009 |
Cariogenic and erosive potential of the medication used by HIV-infected children: pH and sugar concentration.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-HIV Agents; Azithromycin; Cariogenic Agents; Chromatography, Thin Layer; Dental Caries; Dideoxynucleosides; Fructose; Glucose; HIV Infections; Humans; Hydrogen-Ion Concentration; Lactose; Sucrose; Tooth Erosion; Zidovudine | 2008 |
Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3.
Topics: Animals; Anti-HIV Agents; Binding Sites; Biological Transport, Active; CHO Cells; Cricetinae; Cricetulus; Dideoxynucleosides; Drug Interactions; Humans; Kinetics; Lamivudine; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Reverse Transcriptase Inhibitors; Transfection; Zidovudine | 2009 |
Improvement of sensitivity and selectivity of high-performance liquid chromatography for anti-retroviral drugs (non-reverse transcriptase inhibitors) by diamond-electrode electrochemical and fluorescence detection.
Topics: Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Electrochemical Techniques; Fluorescence; Humans; Lamivudine; Linear Models; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Water; Zidovudine | 2009 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Intercellular Adhesion Molecule-1; Longitudinal Studies; Male; Matrix Metalloproteinase 9; Middle Aged; Peroxidase; Risk Factors; Vascular Cell Adhesion Molecule-1; Viral Load; Zidovudine | 2009 |
FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
Topics: Dideoxynucleosides; Drug Approval; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration; Zidovudine | 2009 |
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
[Durability and tolerability of long-term nevirapine-based HAART].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Comorbidity; Dideoxynucleosides; Female; Hepatitis, Viral, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lipids; Liver Function Tests; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Viral Load; Young Adult; Zidovudine | 2010 |
Recent FDA approvals and changes.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Capsules; Cyclopropanes; Dideoxynucleosides; Drug Approval; Drug Labeling; Drugs, Generic; HIV Infections; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration; Zidovudine | 2010 |
[Coinfection with HIV and HCV: abacavir and ribavirine, why not?].
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Ribavirin; Zidovudine | 2012 |
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
Topics: Administration, Oral; Antirheumatic Agents; Chemistry, Pharmaceutical; Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Solutions; Tablets; Therapeutic Equivalency; Zidovudine | 2012 |
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
Topics: Adenine; Algorithms; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Genomics; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Least-Squares Analysis; Mutation; Nucleosides; Organophosphonates; Phenotype; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; Zidovudine | 2012 |
[Acute hemolytic anemia in an HIV patient after inhalation of amyl nitrite].
Topics: Administration, Inhalation; Adult; Amyl Nitrite; Anemia, Hemolytic; Anti-HIV Agents; Diagnosis, Differential; Dideoxynucleosides; HIV Infections; Humans; Illicit Drugs; Inhalant Abuse; Iraq; Lamivudine; Male; Travel; Zidovudine | 2012 |
In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA Primers; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Telomerase; Tenofovir; Zidovudine | 2012 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2013 |
Prevalence and risk factors of low bone mineral density in Korean HIV-infected patients: impact of abacavir and zidovudine.
Topics: Adult; Anti-HIV Agents; Asian People; Body Mass Index; Bone Density; Bone Diseases, Metabolic; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Odds Ratio; Osteoporosis; Prevalence; Republic of Korea; Retrospective Studies; Risk Factors; Zidovudine | 2013 |
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Blood Coagulation; Cardiovascular Diseases; Dideoxynucleosides; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Organophosphonates; Risk Factors; Tenofovir; Zidovudine | 2014 |
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Estonia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Zidovudine | 2016 |
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coinfection; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir; Zidovudine | 2015 |
Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection.
Topics: Animals; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; Hep G2 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mice; Nanogels; Polyethylene Glycols; Polyethyleneimine; Polylysine; Reverse Transcriptase Inhibitors; Zidovudine | 2015 |
[CLINICAL AND PHARMACOECONOMIC RESULTS OF THE USAGE OF VARIOUS HIV REVERSE TRANSCRIPTASE INHIBITORS IN THE SCHEMES OF ANTIRETROVIRAL THERAPY OF PATIENT RECEIVING THERAPY FOR THE CHRONIC HEPATITIS C VIRUS].
Topics: Adult; Alanine Transaminase; Biomarkers; Blood Platelets; CD4-Positive T-Lymphocytes; Cell Count; Coinfection; Dideoxynucleosides; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2016 |
Zidovudine, abacavir and lamivudine increase the radiosensitivity of human esophageal squamous cancer cell lines.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Dideoxynucleosides; DNA Damage; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Lamivudine; Radiation Tolerance; Radiation-Sensitizing Agents; Telomerase; Telomere; Zidovudine | 2016 |
Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Indonesia; Lamivudine; Male; Prospective Studies; Ritonavir; Thailand; Treatment Outcome; Vietnam; Viral Load; Zidovudine | 2016 |
Mitochondrial compromise in 3-year old patas monkeys exposed in utero to human-equivalent antiretroviral therapies.
Topics: Animals; Anti-HIV Agents; Bone Marrow Cells; Brain; Dideoxynucleosides; DNA, Mitochondrial; Drug Therapy, Combination; Erythrocebus patas; Female; Gestational Age; Heart; Lamivudine; Mitochondria; Mitochondria, Heart; Oxygen Consumption; Pregnancy; Prenatal Exposure Delayed Effects; Zidovudine | 2016 |
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Nevirapine; Randomized Controlled Trials as Topic; Stavudine; Surveys and Questionnaires; Uganda; Zambia; Zidovudine | 2017 |
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2017 |
First-line antiretroviral drug discontinuations in children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; South Africa; Stavudine; Withholding Treatment; Zidovudine | 2017 |
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV-1; Lamivudine; Lopinavir; Nelfinavir; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 2017 |
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.
Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine | 2017 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
Toxicity and genotoxicity induced by abacavir antiretroviral medication alone or in combination with zidovudine and/or lamivudine in Drosophila melanogaster.
Topics: Animals; Anti-HIV Agents; Dideoxynucleosides; DNA Damage; Drosophila melanogaster; Drug Synergism; Lamivudine; Mutation; Recombination, Genetic; Zidovudine | 2019 |
Multisystem impairment in South African adolescents with Perinatally acquired HIV on antiretroviral therapy (ART).
Topics: Adolescent; Anti-Retroviral Agents; Cardiovascular Diseases; CD4 Lymphocyte Count; Child; Cognition Disorders; Cross-Sectional Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Kidney Diseases; Male; Respiratory Tract Diseases; South Africa; Viral Load; Zidovudine | 2019 |
Abacavir versus Zidovudine-based regimens for treatment of HIV-infected children in resource limited settings: a retrospective cohort study.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Developing Countries; Dideoxynucleosides; Ethiopia; Female; HIV Infections; Humans; Male; Retrospective Studies; Zidovudine | 2020 |
Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
Topics: Anti-HIV Agents; Antibodies, Neutralizing; Antibody-Dependent Cell Cytotoxicity; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; HIV Antibodies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Ritonavir; Viral Load; Zidovudine | 2020 |